Replies to post #212138 on Biotech Values

[Whalatane]

PRTO thx for the follow up Dew. Very much appreciate your experience and knowledge .

If you are ever up for a deep dive into PRTO perhaps you could comment on the following

http://www.jvascsurg.org/article/S0741-5214(16)31237-X/fulltext
.

Poster Poorgrad called it on the early Patency trials and was right on in his analysis .
Their final P 3 tho is only with Radiocephalic fistulas and I believe at the highest ( 30ug ) dose .

Must admit to some bias here .
I've been on the dialysis floor and watched patients being dialyzied . Talked to my wife's patients at Xmas parties. Listened to her weekly venting on the problems with fistula patency .
Anything that can safely extend the time before these fistulas re occlude or have to be abandoned would be of significant benefit ...for both patient and ESRD treatment cost .

The final trial is being run at UCSF by one of the most respected vascular surgeons in the State .
Appreciate your review of the link above when / if you have time .

Note from the link

In patients with radiocephalic fistulas, 30 µg significantly improved primary and secondary patency. Vonapanitase 30 µg decreased the rate of procedures to restore or to maintain patency in the analysis that included all patients and in the subset with radiocephalic fistulas.

Kiwi